Atara Biotherapeutics (ATRA) EV to EBITDA (2014 - 2026)

Atara Biotherapeutics (ATRA) has reported EV to EBITDA for 13 consecutive years, with 33.06 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBITDA fell 247.11% year-over-year to 33.06; the trailing twelve-month figure through Jun 2026 stood at 10.97 (down 222.73% YoY), and the FY2025 full-year result was 6.09, up 988.92% from the prior year.
• EV to EBITDA declined to 33.06 in Q2 2026 per ATRA's latest filing, from 17.28 in the prior quarter.
• Across five years, EV to EBITDA topped out at 22.47 in Q2 2025 and bottomed at 85.22 in Q4 2025.
• Historically, EV to EBITDA has averaged 10.65 across 5 years, with a median of 1.05 in 2022.
• The widest YoY moves for EV to EBITDA: up 2520.64% in 2025, down 17044.7% in 2025.
• Over 5 years, EV to EBITDA stood at 0.95 in 2022, then jumped by 94.98% to 0.05 in 2023, then slumped by 9718.64% to 4.68 in 2024, then slumped by 1719.07% to 85.22 in 2025, then jumped by 61.21% to 33.06 in 2026.
• According to Business Quant data, EV to EBITDA over the past three periods registered 33.06, 17.28, and 85.22 for Q2 2026, Q1 2026, and Q4 2025 respectively.